EGFR and non-small cell lung carcinoma: EGFR (epidermal growth factor receptor) mutation is a major oncogenic driver in non-small cell lung carcinoma (NSCLC), and inhibition of EGFR signaling by EGFR-tyrosine kinase inhibitors (TKIs) represent the optimal clinical treatment strategy for NSCLC patients with EGFR mutations.